Lorglumide
Lorglumide (CR-1409) is an orally active Cholecystokinin Receptor antagonist. Lorglumide inhibits pancreatic cancer cell proliferation, induces G0/G1 phase arrest and apoptosis, and downregulates MMP-2. Lorglumide inhibits gastrin-stimulated Ornithine decarboxylase activity and DNA synthesis, and shows low CCKA/CCKB selectivity. Lorglumide blocks Caerulein (HY-A0190)-induced exocrine pancreatic secretion and pancreatic tissue hyperplastic changes in rats, and inhibits gallbladder emptying induced by exogenous and endogenous CCK in mice. Lorglumide can be used in research related to pancreatic cancer and pancreatic exocrine function.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 97964-56-2
- 分子式: C22H32Cl2N2O4
- 分子量:459.41
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
|
CCKAR |
CCKBR |
MMP-2 |
体外実験
Lorglumide (10-5-10-4 M; 24 h) reduces Mia PaCa-2 invasion, reported as 77.6 invading cells under the 10-4 M condition marked in Table V[2].
Lorglumide (10-5 M; 24 h) attenuates MMP-2 expression in Mia PaCa-2 cells[2].
Lorglumide (CR1409) displaces gastrin binding on AR42J cells with an IC50 of 3 µM; it competitively antagonizes gastrin-stimulated ODC activity in AR42J cells with a pA2 of 6.5[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mia PaCa-2 human pancreatic adenocarcinoma cells
-
Concentration:10-5 M, 10-4 M, 10-3 M
-
Incubation Time:24, 48, and 72 h
-
Result:Inhibited Mia PaCa-2 cell viability, with 10-4 M reducing viability to 52.1% after 48 h.
-
Cell Line:Mia PaCa-2 human pancreatic adenocarcinoma cells
-
Concentration:10-5 M, 10-4 M
-
Incubation Time:48 h
-
Result:Induced G0/G1 cell-cycle arrest in Mia PaCa-2 cells, with 10-4 M producing 40.3% G0/G1 cells after 48 h.
-
Cell Line:Mia PaCa-2 human pancreatic adenocarcinoma cells
-
Concentration:10-5 M, 10-4 M
-
Incubation Time:48 h
-
Result:Induced apoptosis in Mia PaCa-2 cells, with 10-4 M producing a 27.1% apoptosis index after 48 h.
-
Cell Line:Mia PaCa-2 human pancreatic adenocarcinoma cells
-
Concentration:10-5 M (procedure)
10-4 M (Table V) -
Incubation Time:24 h
-
Result:Reduced Mia PaCa-2 invasion, with 77.6 invasion cells reported at the Table V-labeled 10-4 M condition.
-
Cell Line:Mia PaCa-2 human pancreatic adenocarcinoma cells
-
Concentration:10-5 M
-
Incubation Time:24 h
-
Result:Attenuated MMP-2 expression in Mia PaCa-2 cells.
体内実験
Lorglumide (10 mg/kg; intraperitoneal injection; three times daily; for 5 consecutive days) attenuates Caerulein-induced pancreatic growth and increased enzyme content in vivo, without affecting Bombesin-induced pancreatic growth in vivo[1].
Lorglumide (CR1409) (oral or intraperitoneal) dose-dependently inhibits egg yolk-induced gallbladder emptying in mice, with ED50 values of 1.1 mg/kg for intraperitoneal administration and 5.0 mg/kg for oral administration; it effectively antagonizes CCK-8-induced gallbladder contraction in mice, with ED50 values of 1.9 mg/kg for intraperitoneal administration and 2.0 mg/kg for oral administration[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:OFA (Sprague-Dawley-derived, 180-200 g)[1]
-
Dosage:5 mg/kg; 10 mg/kg
-
Administration:i.p.; single pretreatment; 15 min before caerulein
-
Result:Reduced caerulein‑stimulated pancreatic juice flow and protein output dose‑dependently at 5 mg/kg and 10 mg/kg, while barely altered Bombesin‑stimulated pancreatic secretion at both doses.
-
Animal Model:OFA (Sprague-Dawley-derived, 60-80 g)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; three times daily; 5 days; 15 min before each caerulein dose
-
Result:Reduced caerulein-evoked elevations in pancreatic weight, total pancreatic protein, amylase and trypsin contents upon co-administration with Caerulein, whereas failed to modify bombesin-triggered changes in pancreatic weight, protein, DNA, amylase and trypsin contents when co-administered with bombesin.
- Mitochondrial membrane-potential fluorescent assay
- Annexin V plus membrane-impermeant dye apoptosis staining
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- PCNA Immunodetection Proliferation Assay
- Flow cytometric DNA-content cell-cycle staining
- Protocol for Cell Counting and Cell Density Analysis
- Mitochondrial membrane-potential and mitochondrial mass staining
- Apoptosis Solutions
- MTT Cell Proliferation Assay
化学情報
-
CAS 番号 97964-56-2
-
分子量 459.41
-
分子式 C22H32Cl2N2O4
-
SMILES
O=C(O)CCC(NC(C1=CC=C(Cl)C(Cl)=C1)=O)C(N(CCCCC)CCCCC)=O
-
別名
CR-1409
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- Lorglumide
- 97964-56-2
- CR-1409
- CR1409
- CR 1409
- Cholecystokinin Receptor
- MMP
- Ornithine decarboxylase (ODC)
- Apoptosis
- CCK Receptor
- Matrix metalloproteinases
- Ornithine Decarboxylase
- CCK receptor
- CCK-1 receptor
- CCK-B/gastrin receptor
- MMP-2
- amylase release
- apoptosis
- cholecystokinin
- exocrine pancreatic tumors
- gallbladder contraction
- pancreatic cancer
- Inhibitor
- inhibitor
- inhibit